TBG Diagnostics

TBG Diagnostics developed a broad portfolio of molecular diagnostic devices, particularly for HLA typing and infectious disease detection. As of late 2022, the company sold its controlling interest in TBG Biotechnology Corporation and related entities; before divestiture, it held several regulatory approvals (CE mark, US FDA 510k, Taiwan FDA, China NMPA). TBG Diagnostics operated as a global player in molecular diagnostics, especially HLA-based immunogenetics and infectious disease assays, with both commercialized and pipeline products. As of November 2022, TBG Diagnostics Limited sold its controlling interest in its core operating subsidiaries (TBG Biotechnology Corporation and TBG Biogene Inc.) to Medigen Biotechnology Corp, marking the end of its independent operations. The pipeline encompassed 21 products, with regulatory approvals across major markets. The company focused on device/diagnostic modalities, not therapeutic drugs.